SCHEMBL5455851

SCHEMBL5455851

NC(=O)c1c(NC(=O)Nc2ccc(OC(F)F)cc2)sc2c(Cl)c(O)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 1/20 0.40
KCNH2 Q12809 8/20 0.39
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
ALDH1A1 P00352 4/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455848 0.85 KMT2A (0.43) KMT2AMEN1MAPTSMN1; SMN2LMNA
SCHEMBL5451260 0.75 EPHX2 (0.51) STING1KMT2AMEN1MAPTNPSR1
SCHEMBL5456366 0.74 FLT3 (0.52) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL5466113 0.73 FLT3 (0.42) KMT2AMEN1MAPTSMN1; SMN2NPSR1
SCHEMBL5466938 0.73 CA12 (0.44) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4121665 0.72 KMT2A (0.58) STING1KMT2AMEN1MAPTSMN1; SMN2
Urea SCHEMBL4110289 0.72 MAPT (0.61) STING1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL5460181 0.72 GRIN2C (0.44) KMT2AMEN1MAPTSMN1; SMN2LMNA
SCHEMBL5455834 0.71 MEN1 (0.48) KMT2AMEN1MAPTSMN1; SMN2LMNA
SCHEMBL4118526 0.71 MAPT (0.66) STING1KMT2AMEN1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 STING1 1658/4885KMT2A 4785/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.